Onco Wiki / Red flag

First exposure to a monoclonal antibody (rituximab, obinutuzumab, brentuximab vedotin, mo...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Red Flag Origin

Trigger Logic

{
  "all_of": [
    {
      "comparator": "==",
      "finding": "cycle_number",
      "threshold": 1
    },
    {
      "any_of": [
        {
          "finding": "regimen_contains_rituximab",
          "value": true
        },
        {
          "finding": "regimen_contains_obinutuzumab",
          "value": true
        },
        {
          "finding": "regimen_contains_brentuximab",
          "value": true
        },
        {
          "finding": "regimen_contains_mogamulizumab",
          "value": true
        },
        {
          "finding": "regimen_contains_alemtuzumab",
          "value": true
        },
        {
          "finding": "regimen_contains_daratumumab",
          "value": true
        }
      ]
    }
  ],
  "type": "composite_score"
}

Notes

Anti-CD20 cycle-1 infusion-reaction rate: 30-77% any-grade for rituximab (Lim et al. 2012); 65% for obinutuzumab cycle-1 vs <10% by cycle-3. Premedication: paracetamol 1g + diphenhydramine 25-50 mg PO 30-60 min pre-infusion; methylprednisolone 80-100 mg IV when CD20 burden is high. Initial infusion rate 50 mg/h, escalate by 50 mg/h every 30 min if no reaction, max 400 mg/h (rituximab). Mogamulizumab and brentuximab have their own premedication regimens — engine should select per drug.

Used By

No reverse references found in the YAML corpus.